EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY-NC 4.0

Treatment of atopic dermatitis with abrocitinib in real practice in Spain: efficacy and safety results from a 24‐week multicenter study

Jose Carlos Armario-Hita, Jose Juan Pereyra-Rodriguez iD, Alicia González-Quesada, Pedro Herranz, Ricardo Suarez, Manuel Galan-Gutiérrez, Mercedes Rodríguez-Serna, Javier Ortiz de Frutos, José Manuel Carrascosa iD, Esther Serra-Baldrich, Mariano Ara-Martin, Ignasi Figueras-Nart und 3 weitere

International Journal of Dermatology · 2024

DOI: 10.1111/ijd.17344 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift International Journal of Dermatology, 2024. Verfasst von Jose Carlos Armario-Hita und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, University Hospital of Puerto Real, University of Cádiz, Spain. Hauptthemen laut MEDLINE: Dermatitis, Atopic, Severity of Illness Index, Quality of Life. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 18 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Abrocitinib, a selective JAK 1 inhibitor, was recently approved in Europe. Despite its approval, real‐world data on its efficacy and safety in treating moderate‐to‐severe atopic dermatitis (AD) remains limited.

Objectives

This study aimed to evaluate the short‐term effectiveness and safety of abrocitinib in a real‐life setting for patients with moderate‐to‐severe AD.

Methods

We conducted a retrospective multicenter study involving adult patients with moderate‐to‐severe AD who started abrocitinib treatment between May 1, 2023, and September 30, 2023, in 15 Spanish hospitals. Treatment doses were 100 or 200 mg daily, based on clinical assessment. Data collection included patient demographics, AD history, comorbidities, previous treatments, and disease severity indicators such as SCORing atopic dermatitis (SCORAD), Eczema Area and Severity Index (EASI), body surface area, and Peak Pruritus NRS scores at baseline, 4, 12, and 24 weeks. Quality of life was measured using the Dermatology Life Quality Index (DLQI), and safety was assessed by monitoring adverse reactions and various biochemical parameters.

Results

The cohort comprised 76 patients with an average age of 33.93 years; 57.89% were male. Before abrocitinib, 36.84% were naïve to advanced therapies. The baseline mean scores were SCORAD 47.04, EASI 21.79, and DLQI 15.01. At Week 24, there were significant improvements: EASI was reduced to 2.81, and 70.58% of the patients achieved EASI 75. However, 18.42% discontinued treatment mainly due to inefficacy or adverse effects. The safety profile was favorable, with 22.37% reporting mild adverse events (AEs) and one serious case of cutaneous lymphoma.

Conclusions

This first Spanish series assessing abrocitinib in real‐world conditions reveals a significant improvement in AD symptoms and quality of life in a range of severity and prior treatment failures. Abrocitinib was well‐tolerated, with few serious AEs, highlighting its potential as an effective treatment option for AD.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Dermatitis, AtopicSeverity of Illness IndexQuality of LifeHumansMaleFemaleAdultRetrospective StudiesSpainMiddle AgedTreatment OutcomeSulfonamidesPyrimidinesYoung Adult

Stichwörter der Autor:innen

JAK inhibitorsSpainabrocitinibatopic dermatitistreatment

Substanzen

abrocitinibSulfonamidesPyrimidines

Autor:innen und Institutionen

  • Department of Dermatology, University Hospital of Puerto Real, University of Cádiz, Spain.
  • Department of Dermatology, University Hospital Virgen del Rocío, Sevilla, Spain.
  • Department of Medicine, School of Medicine, University of Sevilla, Sevilla, Spain.
  • Department of Dermatology, University Hospital Dr. Negrin, Gran Canarias, Spain.
  • Department of Dermatology, University Hospital La Paz, Madrid, Spain.
  • Department of Dermatology, University Hospital Gregorio Marañón, Madrid, Spain.

ORCID-Profile: Jose Juan Pereyra-Rodriguez, José Manuel Carrascosa

Zitieren

APA

Armario-Hita, J. C., Pereyra-Rodriguez, J. J., González-Quesada, A., Herranz, P., Suarez, R., Galan-Gutiérrez, M., Rodríguez-Serna, M., Ortiz de Frutos, J., Carrascosa, J. M., Serra-Baldrich, E., Ara-Martin, M., Figueras-Nart, I., Silvestre, J. F., Zaragoza-Ninet, V., & Ruiz-Villaverde, R. (2024). Treatment of atopic dermatitis with abrocitinib in real practice in Spain: efficacy and safety results from a 24‐week multicenter study. International Journal of Dermatology. https://doi.org/10.1111/ijd.17344

Vancouver

Armario-Hita JC, Pereyra-Rodriguez JJ, González-Quesada A, Herranz P, Suarez R, Galan-Gutiérrez M, et al. Treatment of atopic dermatitis with abrocitinib in real practice in Spain: efficacy and safety results from a 24‐week multicenter study. International Journal of Dermatology. 2024. doi:10.1111/ijd.17344

BibTeX
@article{ArmarioHita2024,
  author = {Armario-Hita, Jose Carlos and Pereyra-Rodriguez, Jose Juan and González-Quesada, Alicia and Herranz, Pedro and Suarez, Ricardo and Galan-Gutiérrez, Manuel and Rodríguez-Serna, Mercedes and Ortiz de Frutos, Javier and Carrascosa, José Manuel and Serra-Baldrich, Esther and Ara-Martin, Mariano and Figueras-Nart, Ignasi and Silvestre, Juan Francisco and Zaragoza-Ninet, Violeta and Ruiz-Villaverde, Ricardo},
  title = {Treatment of atopic dermatitis with abrocitinib in real practice in Spain: efficacy and safety results from a 24‐week multicenter study},
  journal = {International Journal of Dermatology},
  year = {2024},
  doi = {10.1111/ijd.17344}
}
Kostenlos starten →